NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects

Author:

Belhadj Sami123ORCID,Khurram Aliya1ORCID,Bandlamudi Chaitanya4ORCID,Palou-Márquez Guillermo5ORCID,Ravichandran Vignesh4ORCID,Steinsnyder Zoe1ORCID,Wildman Temima1ORCID,Catchings Amanda1ORCID,Kemel Yelena6ORCID,Mukherjee Semanti1ORCID,Fesko Benjamin6ORCID,Arora Kanika4ORCID,Mehine Miika4ORCID,Dandiker Sita1ORCID,Izhar Aalin1ORCID,Petrini John6ORCID,Domchek Susan7ORCID,Nathanson Katherine L.7ORCID,Brower Jamie7ORCID,Couch Fergus8ORCID,Stadler Zsofia1ORCID,Robson Mark19ORCID,Walsh Michael110ORCID,Vijai Joseph111ORCID,Berger Michael4ORCID,Supek Fran512ORCID,Karam Rachid3ORCID,Topka Sabine12ORCID,Offit Kenneth12611ORCID

Affiliation:

1. 1Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.

2. 2Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.

3. 3Ambry Genetics, Aliso Viejo, California.

4. 4Department of Pathology, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

5. 5Genome Data Science, Institute for Research in Biomedicine (IRB Barcelona), Barcelona institute for Science and Technology, Barcelona, Spain.

6. 6Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York.

7. 7Basser Center for BRCA and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

8. 8Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

9. 9Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

10. 10Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.

11. 11Department of Medicine, Weill Cornell Medical College, New York, New York.

12. 12Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.

Abstract

Abstract Purpose: To explore the role of NBN as a pan-cancer susceptibility gene. Experimental Design: Matched germline and somatic DNA samples from 34,046 patients were sequenced using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and presumed pathogenic germline variants (PGV) identified. Allele-specific and gene-centered analysis of enrichment was conducted and a validation cohort of 26,407 pan-cancer patients was analyzed. Functional studies utilized cellular models with analysis of protein expression, MRN complex formation/localization, and viability assessment following treatment with γ-irradiation. Results: We identified 83 carriers of 32 NBN PGVs (0.25% of the studied series), 40% of which (33/83) carried the Slavic founder p.K219fs. The frequency of PGVs varied across cancer types. Patients harboring NBN PGVs demonstrated increased loss of the wild-type allele in their tumors [OR = 2.7; confidence interval (CI): 1.4–5.5; P = 0.0024; pan-cancer], including lung and pancreatic tumors compared with breast and colorectal cancers. p.K219fs was enriched across all tumor types (OR = 2.22; CI: 1.3–3.6; P = 0.0018). Gene-centered analysis revealed enrichment of PGVs in cases compared with controls in the European population (OR = 1.9; CI: 1.3–2.7; P = 0.0004), a finding confirmed in the replication cohort (OR = 1.8; CI: 1.2–2.6; P = 0.003). Two novel truncating variants, p.L19* and p.N71fs, produced a 45 kDa fragment generated by alternative translation initiation that maintained binding to MRE11. Cells expressing these fragments showed higher sensitivity to γ-irradiation and lower levels of radiation-induced KAP1 phosphorylation. Conclusions: Burden analyses, biallelic inactivation, and functional evidence support the role of NBN as contributing to a broad cancer spectrum. Further studies in large pan-cancer series and the assessment of epistatic and environmental interactions are warranted to further define these associations.

Funder

National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3